Please ensure Javascript is enabled for purposes of website accessibility

AstraZeneca COVID-19 Vaccine Shows Promise in 2-Dose Animal Trial

By Eric Volkman – Jun 23, 2020 at 10:51PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The results indicate that a prime dose plus a booster notably increases its effect.

The results of a clinical trial in pigs administered AstraZeneca's (AZN 0.83%) COVID-19 vaccine indicate that two doses of it could be effective in treating the disease. On Tuesday, the Pirbright Institute -- the U.K. researcher conducting the trial -- said that a prime dose followed by a booster produced a stronger immune response than a single dose.

The study was specifically designed to research whether a prime/booster combination of AZD1222 would be notably more efficacious. "This finding in pigs is important as it reveals that two doses of the new vaccine could potentially give significantly more protection in humans than a single dose, and therefore provide a clinical benefit," Pirbright wrote.

Researcher holding a pig while peer writes in a notebook.

Image source: Getty Images.

However, although pigs are physiologically more similar to humans than many other animals, clinical studies conducted on them indicate only potential for us, and are not a guarantee of success. Trials on human subjects are thus necessary following such research.

Last month, it was announced that researchers at the University of Oxford had begun enrolling people for a phase 2 clinical trial of AZD1222. This will be a significantly expanded trial compared to phase 1, involving 10,260 subjects.

The storied U.K. university is where AZD1222 was created; AstraZeneca subsequently licensed the vaccine. As a global pharmaceutical company, AstraZeneca has already made arrangements to produce and distribute the vaccine at cost. Among other deals it has agreed with Europe's Inclusive Vaccines Alliance to provide up to 400 million doses throughout that continent when it is approved and available.

The company recently signed several agreements that will allow it to produce over 2 billion doses.

On Tuesday, AstraZeneca's shares rose by nearly 1.6%, outpacing the gains of the broader stock market.

Eric Volkman has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

AstraZeneca PLC Stock Quote
AstraZeneca PLC
AZN
$55.30 (0.83%) $0.46

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
326%
 
S&P 500 Returns
102%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 10/03/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.